NCT05583669View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

May 11, 2023

Study Completion Date

May 11, 2023

Conditions
Netherton Syndrome
Interventions
DRUG

DS-2325a

Subcutaneous injection (starting dose 300 mg)

DRUG

Placebo

Subcutaneous injection

Trial Locations (1)

33126

Quotient Sciences -Miami, Miami

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT05583669 - A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects | Biotech Hunter | Biotech Hunter